Opinion
Video
Treatment Landscape and Sequencing of Therapies
Author(s):
Panelists discuss how advancements in biomarker and genetic testing, along with updated treatment guidelines, are transforming the diagnosis and management of prostate cancer, emphasizing the importance of personalized approaches in optimizing patient outcomes.
Can you please tell us about the significance of biomarker and genetic testing, as well as imaging, in the diagnosis of patients with prostate cancer.
- Briefly review guidelines for testing (NCCN Guidelines, Prostate Cancer)
- How do these results impact patient management? (eg, prognosis, risk stratification, treatment selection)
What are the key factors you consider in risk stratification of your patients? What clinical characteristics and existing biomarkers help guide your assessment?
What promising biomarkers have emerged that may help detect early signs of prostate cancer progression? (Logan Cancers 2023, Kumaraswamy JCI Insight 2023, please highlight any others)
